-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, PeptiDream announced a new multi-target collaboration and licensing agreement with Merck, USA-based through a subsidiary, focused on the discovery and development of novel peptide-drug conjugates ("PDCs"
).
PeptiDream will receive an advance payment and will be eligible to receive payments based on the achievement of certain developmental, regulatory and commercial milestones, which may total up to $2.
1 billion and royalties
on net sales of any cooperative products.
1 billion for Merck
PeptiDream will provide peptide candidate identified from its proprietary Peptide Discovery Platform System ("PDPS") technology as PDCs targeting targets of interest to Merck
.
Merck will have exclusive rights to the peptide candidate bound to the cytotoxic payload and will be responsible for all development aspects
of any PDC product resulting from the collaboration.
The new collaboration and licensing agreement builds on a long-standing relationship between the two companies that began with a multi-target discovery and optimization collaboration
in April 2015.
In addition, PeptiDream announced that it has signed a research collaboration and licensing agreement with Eli Lilly of America focused on the discovery and development of novel peptide-drug conjugates ("PDCs"
).
PeptiDream will receive an advance payment and will be eligible to receive payments based on the achievement of certain developmental, regulatory and commercial milestones, which may total up to $1.
235 billion, and will be eligible for royalties
on net sales of any such products.
S.
Eli Lilly $1.
235 billion
Under this protocol, PeptiDream will utilize its proprietary Peptide Discovery Platform System ("PDPS") technology to identify high-affinity macrocyclic peptide ligands selected by Lilly for selected targets of interest, capable of delivering Lilly-conjugated
payloads to certain cells and tissues of interest to Lilly.
PeptiDream will lead peptide discovery and optimization efforts, and Eli Lilly will lead payload discovery and optimization efforts
.
Eli Lilly will be responsible for all aspects of the development of
any PDC products resulting from the collaboration.
The new research collaboration and license agreement builds on a long-standing relationship between the two companies, with the signing of the first collaboration and license agreement in December 2013, followed by the signing of a non-exclusive license of PeptiDream's proprietary PDPS technology in March 2016, which explicitly excludes work on
the PDC project.
